BDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Becton Dickinson (BDX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company demonstrates solid financial performance and resilience in economic downturns, the lack of a meaningful catalyst, bearish technical indicators, and neutral sentiment from analysts suggest that the stock may remain range-bound in the near term. A hold position is recommended until clearer growth signals or catalysts emerge.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 41.673, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 153.312, and resistance is at 158.236. Overall, the technical indicators suggest a lack of upward momentum.
Strong financial performance in Q1 2026, with revenue up 1.63% YoY and net income up 26.07% YoY.
Resilience during economic downturns, as highlighted in recent news.
CE marking for the Liverty™ TIPS Stent Graft, expanding treatment options.
Analysts highlight a lack of meaningful catalysts and ongoing headwinds (e.g., Alaris) for FY26 and FY
Bearish technical indicators and range-bound stock movement.
High options volume put-call ratio reflects bearish sentiment.
In Q1 2026, Becton Dickinson reported revenue growth of 1.63% YoY to $5.25 billion, net income growth of 26.07% YoY to $382 million, and EPS growth of 28.85% YoY to $1.34. Gross margin improved to 45.91%, up 5.13% YoY, reflecting strong operational performance.
Analysts are mixed to neutral on BDX. RBC Capital and Goldman Sachs maintain neutral ratings with price targets of $175 and $167, respectively, citing balanced upside/downside drivers and lack of catalysts. Argus and Citi are more optimistic, with buy ratings and price targets of $180 and $198, respectively, citing the company's repositioning as a pure-play MedTech firm and strong fundamentals.
